Data Sheet (Cat.No.T8399)

TargetMol

Crizotinib hydrochloride

Chemical Properties



CAS No. :	1415560-69-8
Formula:	C21H23Cl3FN5O
Molecular Weight:	486.8
Storage:	Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met, with IC50 values of 20 nM and 8 nM, respectively.
Targets(IC50)	ALK,Autophagy,c-Met/HGFR,ROS,ROS Kinase
In vitro	Crizotinib hydrochloride(PF-2341066)potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC(50) value, 24 nmol/L).?In biochemical and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacologically relevant concentrations across a panel of >120 diverse kinases.?PF-2341066 potently inhibited cell proliferation, which was associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC(50) values, approximately 30 nmol/L) but not ALK-negative lymphoma cells[1].

Solubility Information

Solubility	DMSO: 10 mg/mL (20.54 mM),Sonication is recommended. H2O: 50 mg/mL (102.71 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0542 mL	10.2712 mL	20.5423 mL
5 mM	0.4108 mL	2.0542 mL	4.1085 mL
10 mM	0.2054 mL	1.0271 mL	2.0542 mL
50 mM	0.0411 mL	0.2054 mL	0.4108 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322.

Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63.